Sudhir Bansal
Endocrinology, Diabetes & Metabolism · Warwick, RINPI 1356373633
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,566 of the $38,219 with a category attached, or 72.1%. AstraZeneca accounts for 66.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $22,118 and has fallen 98.2% since, to $403 in 2025.
Across 272 payments — averaging $140.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$25K
- Sanofi-aventis U.S. LLC$5K
- Corcept Therapeutics$5K
- Amarin Pharma, Inc.$1K
- Novartis$582
- Amgen$385
- plus $2K from 20 others
Across 75 payments — averaging $32,109 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1M
- Pfizer$840K
- Novartis$375K
- AbbVie$182K
- Vanda Pharmaceuticals Inc.$7K
What the payments were for
- Consulting fees$2,2506%
- Speaking & faculty fees$27,56672%
- Travel & lodging$2,7957%
- Food & beverage$5,60215%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 61 | $25,284 |
| Sanofi-aventis U.S. LLC | 42 | $4,703 |
| Corcept Therapeutics | 19 | $4,608 |
| Amarin Pharma, Inc. | 42 | $1,145 |
| Novartis | 7 | $582 |
| Amgen | 16 | $385 |
| Boehringer Ingelheim | 17 | $306 |
| Lilly USA, LLC | 15 | $241 |
| Novo Nordisk | 8 | $196 |
| Lifescan, Inc. | 5 | $96 |
| AbbVie | 4 | $91 |
| Johnson & Johnson | 6 | $83 |
| Shire North American Group Inc | 4 | $66 |
| Antares Pharma, Inc. | 4 | $64 |
| Merck | 4 | $54 |
| Dexcom, Inc. | 3 | $53 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Mannkind Corporation | 2 | $42 |
| Abbott | 2 | $34 |
| Radius Health, Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Medtronic | 1 | $23 |
| IBSA Pharma Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Valeritas, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,219 in reported general payments places this provider in the 85th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Other endocrinology, diabetes & metabolism in Warwick
- Beatriz DemoranvilleWarwick$5K
- Nathalie CampbellWarwick$766
- Brittany RicciWarwick$321
- Robert DobrzynskiProvidence$245K
- Frank D'alessandroNorth Providence$193K
- Ricardo Correa MarquezEast Providence$94K
- Robert SmithProvidence$80K
- Joseph TucciProvidence$30K
- Judith GilmoreWakefield$11K
- Stephanie CurryJohnston$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.